Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation

Coverage Summary and Scope

Policy CS036.X (effective March 1, 2025) defines UnitedHealthcare coverage for electrical stimulation devices and therapies for pain treatment and muscle rehabilitation. The policy's overall coverage stance is mixed: Functional Electrical Stimulation (FES) and Neuromuscular Electrical Stimulation (NMES) are judged proven and medically necessary in specific, defined clinical circumstances (detailed FES and NMES clinical criteria apply). Other electrical stimulation modalities reviewed (e.g., interferential therapy, MENS, PENS/PNT, PENFS, PNS, PSFS/PNFS, PES/PEMF, restorative neurostimulation, scrambler therapy, translingual stimulation) are characterized as unproven or not medically necessary because evidence is insufficient or inconclusive for most indications.

This policy does not uniformly apply across all states; administrative updates note removal of Louisiana- and Mississippi-specific language and an explicit statement that the policy does not apply to Idaho and Kansas where state-specific versions govern. Refer to the Application section and the policy history for these state applicability notes.

Key thresholds and scope

Effective DateMarch 1, 2025

Policy NumberCS036.X

Proven modalitiesFES; NMES

Unproven/not medically necessary modalities count11

Independent standing tolerance (numeric threshold)>= 3 minutes

Post-recovery threshold (numeric)>= 6 months post-recovery/surgery

Intended audience: clinicians, facility administrators, and payers adjudicating coverage for electrical stimulation therapies. Payer note: when making coverage determinations, adjudicators and providers must check federal, state, or contractual benefit requirements because those requirements govern if they differ from the standard policy and medical records documentation may be requested to assess whether clinical criteria are met.

Functional Electrical Stimulation (FES) — Medical Necessity Criteria

Functional electrical stimulation (FES) is proven and medically necessary as a component of a comprehensive ambulation rehabilitation program in individuals with lower limb paralysis due to spinal cord injury (SCI) when ALL of the following criteria are met:

FES — Medically Necessary

Demonstration of intact lower motor units (L1 and below) (both muscle and peripheral nerves).
Muscle and joint stability for weight bearing at upper and lower extremities that can demonstrate balance and control to maintain an upright support posture independently.
Demonstration of brisk muscle contraction.
Demonstration of sensory perception sufficient for muscle contraction.

Neuromuscular Electrical Stimulation (NMES) — Medical Necessity Criteria

Neuromuscular Electrical Stimulation (NMES) — Medically Necessary Criteria

NMES is proven and medically necessary for treating ANY of the following indications:

ANY of the following

Disuse muscle atrophy
- The nerve supply to the muscle is intact
- The disuse muscle atrophy is not of neurological origin but results from other conditions (e.g., casting, splinting, or contractures)
When used as part of a comprehensive lower limb rehabilitation program following total knee arthroplasty
To improve upper extremity function in persons with partial paralysis following stroke when used as part of a comprehensive rehabilitation program

Unproven / Not Medically Necessary Modalities

The following electrical stimulation modalities are unproven and not medically necessary due to insufficient evidence of efficacy:

ANY of the following

Interferential therapy (IFT) for musculoskeletal disorders/injuries or to facilitate healing of nonsurgical soft tissue injuries or bone fractures
Not medically necessary / unproven
Microcurrent electrical nerve stimulation (MENS)
Not medically necessary / unproven
Percutaneous electrical nerve stimulation (PENS) or percutaneous neuromodulation therapy (PNT)
Not medically necessary / unproven

Evidence-based Coverage Considerations (Narrative)

Pulsed electromagnetic field / pulsed electrical stimulation (PEMF/PES): Evidence is heterogeneous and generally limited. Meta-analyses and systematic reviews report some short-term benefit for pain, stiffness, or function in osteoarthritis and selected postoperative settings, but trials are small, protocols vary, and long-term efficacy is uncertain; larger, standardized RCTs are recommended.

Restorative neurostimulation (ReActiv8): The body of evidence includes a sham-controlled RCT and multiple before–after and follow-up studies reporting improvements in pain and disability; however, assessments note marginal between-group benefit at early endpoints, substantial attrition, and high risk of bias in uncontrolled follow-ups, leading to an overall conclusion of inconclusive evidence that requires additional independent trials.

Scrambler Therapy: Multiple small RCTs, single-arm studies and meta-analyses show inconsistent, low-to-very-low quality evidence with marginal or short-term pain reductions in some neuropathic indications (e.g., CIPN); guideline bodies (ASCO, ESMO) do not recommend routine use outside trials due to uncertainty.

Translingual stimulation / PoNS (TLNS): Small RCTs and pilot studies, often from device-developing centers, suggest possible gait and balance benefits when combined with therapy in TBI or MS, but evidence is limited and inconclusive; further robust, independent trials are needed.

Evidence-quality takeaways

Overall evidence qualityFrequent characterization: low-to-moderate (many areas low-to-very-low)

Coding — CPT / HCPCS / DME / Device Codes

Referenced CPT and Category I / II / III codes (informational list)CPT

0278T	Transcutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each treatment session (includes placement of electrodes)
0720T	Percutaneous electrical nerve field stimulation, cranial nerves, without implantation
0783T	Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment
63650	Percutaneous implantation of neurostimulator electrode array, epidural
63655	Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural
63663	Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed
63664	Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed
63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array

1–10 of 13

1/2

HCPCS / DME / Supplies (including FES-specific note)HCPCS

A4438	Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each
A4543	Supplies for transcutaneous electrical nerve stimulator, for nerves in the auricular region, per month
A4544	Electrode for external lower extremity nerve stimulator for restless legs syndrome
A4556	Electrodes (e.g., apnea monitor), per pair
A4557	Lead wires (e.g., apnea monitor), per pair
A4593	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, controller
A4594	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece, each
A4595	Electrical stimulator supplies, 2 lead, per month (e.g., TENS, NMES)
E0720	Transcutaneous electrical nerve stimulation (TENS) device, two-lead, localized stimulation
E0721	Transcutaneous electrical nerve stimulator for nerves in the auricular region

1–10 of 28

1/3

FES devices mapped to HCPCS E0770 (CMS PDAC verified) - informational (E0770 PDAC mapping list)mixed

E0770*

Only following devices verified by CMS PDAC to be reported with HCPCS E0770: NESS L300 and H200 (Bioness); Odstock ODFS Pace FES System (Odstock Medical/Boston Brace); WalkAide (Innovative Neurotronics); Deluxe Digital Electronic Muscle Stimulator (Drive Medical)

FDA Product Codes / Device Categories referenced for further lookupmixed

GZI	Functional Electrical Stimulation (FES) product code (reference to FDA PMN search)
IPF	Neuromuscular Electrical Stimulation (NMES) for muscle rehabilitation product code
LIH	Interferential Therapy (IFT) product code
NHI	Percutaneous/Peripheral Nerve Stimulation (PNS) & PENS product code
PZR	Peripheral Subcutaneous Field Stimulation (PSFS) product code
GZJ	Microcurrent Electrical Nerve Stimulation (MENS) / TENS / Scrambler Therapy product code
NUH	TENS product code (additional reference)
NGX	TENS product code (additional reference)
QLK	ReActiv8 restorative neurostimulation PMA product code
QHH	IB-Stim PENFS de novo product code

Devices with FDA clearance/approval cited (informational)mixed

PoNS	Portable Neuromodulation Stimulator (de novo approval March 25, 2021) - indicated short-term for gait deficit due to mild-moderate MS as adjunct to supervised therapeutic exercise in patients >=22 years by prescription
ReActiv8	ReActiv8 Implantable Neurostimulation System (PMA approval June 16, 2020) - implanted neurostimulator for multifidus-related CLBP
IB-Stim	IB-Stim PENFS system (de novo DEN180057) approved June 7, 2019 for functional abdominal pain in IBS patients 11-18 years
ST MC-5A / ST-5A	Calmare/Scrambler Therapy TENS device (510k initial 2009, subsequent clearances including 2015 and model replacement 2020)
Deepwave (K061166)	Percutaneous Neuromodulation Pain Therapy System 510(k) April 27, 2006 (Product Code NHI)

Referenced HCPCS code with revised descriptionHCPCS

E0721

HCPCS code E0721 description revised (per 03/01/2025 Summary of Changes)

Provider Actions and Documentation Requirements

Documentation Required

Document FES clinical criteria

Document that each FES medically necessary criterion is met. Required documentation should explicitly address all of the following as applicable: intact lower motor units (L1 and below) including both muscle and peripheral nerve integrity; muscle and joint stability sufficient for weight bearing and ability to maintain upright support posture; demonstration of brisk muscle contraction; sensory perception adequate to permit muscle contraction; high level of patient motivation, commitment, and cognitive ability for device use; independent transfer ability; independent standing tolerance >= 3 minutes; adequate hand and finger function to manipulate device controls; at least 6 months post-recovery from spinal cord injury or restorative surgery; absence of hip or knee degenerative disease; and absence of history of long-bone fracture secondary to osteoporosis.

Document findings supporting intact LMUs (L1 and below) — clinical exam and/or electrodiagnostic testing.
Document objective evidence of muscle contraction and joint stability for weight bearing.
Document sensory exam findings relevant to device use.
Document patient cognitive status, motivation, and ability to comply with training/regimen.
Document transfer and independent standing tolerance (>= 3 minutes).
Document hand/finger function for device manipulation.

Background, Definitions and Mechanisms

Background: The policy reviews many electrical stimulation types including FES, NMES, TENS, PENS/PNT, PENFS, PENFS (auricular), PNS, PSFS/PNFS, IFT, MENS, PES/PEMF, restorative neurostimulation (e.g., ReActiv8), scrambler therapy, and translingual stimulation (PoNS/TLNS). FES is defined as direct application of current to intact nerve fibers to evoke purposeful contractions and bypasses the central nervous system to target motor neurons. NMES uses transcutaneous currents to cause muscle contractions with goals to promote reinnervation, prevent or retard disuse atrophy, relax spasms, and promote voluntary control.

Term	Definition
{"text":"FES","status":""},{"text":"Direct application of electric current to intact nerve fibers to cause purposeful contraction enabling therapeutic or functional goals; bypasses CNS to target motor neurons; used to enable/augment functional movements (e.g., gait, cycling) or therapeutic exercise","status":""}
{"text":"NMES","status":""},{"text":"Transcutaneous electrical currents to cause muscle contractions to promote reinnervation, prevent/retard disuse atrophy, relax spasms, and promote voluntary control for rehabilitation/strength/circulation effects","status":""}
{"text":"TENS","status":""},{"text":"Surface electrodes deliver current to decrease perception of pain by inhibiting afferent pain impulses and/or stimulating endorphin release (analgesic modality)","status":""}
{"text":"PENS","status":""},{"text":"Percutaneous electrical nerve stimulation: minimally invasive needle-based electrical stimulation with needles connected to external power to modulate nerve hypersensitivity for pain; electrodes are percutaneous not cutaneous","status":""}
{"text":"PENFS","status":""},{"text":"Percutaneous electrical nerve field stimulation: auricular/peripheral field stimulation via percutaneous electrodes targeting neurovascular bundles (e.g., external ear) to modulate central pain pathways; mechanism not fully established","status":""}
{"text":"PNS","status":""},{"text":"Peripheral nerve stimulation: implanted or percutaneous electrodes placed near a peripheral nerve to deliver impulses that disrupt transmission of pain signals to reduce pain (implantable and percutaneous systems)","status":""}
{"text":"PES/PEMF","status":""},{"text":"Pulsed electrical stimulation / pulsed electromagnetic field therapies delivering low-frequency electromagnetic or electrical fields hypothesized to aid pain relief, healing, bone/cartilage repair and modulate cellular processes","status":""}
{"text":"ReActiv8","status":""},{"text":"Implantable restorative neurostimulation system targeting multifidus muscle (L2 medial branch) for multifidus-related chronic low back pain to restore neuromuscular control","status":""}
{"text":"PoNS","status":""},{"text":"Portable (translingual) neuromodulation stimulator delivering tongue-based stimulation as adjunct to supervised exercise to potentially improve gait/balance (short-term adjunct for mild-moderate MS per FDA)","status":""}
{"text":"Scrambler Therapy","status":""},{"text":"Noninvasive transdermal therapy (Calmare/ST) applying variable nonlinear waveforms via surface electrodes to present non-pain information to painful area aiming to reduce chronic neuropathic pain","status":""}

Selected Evidence and Key Studies

Overview of the evidence base: The policy cites multiple RCTs, systematic reviews, and HTAs. Key trials and assessments include multicenter RCTs (e.g., WalkAide FES RCT in subacute stroke), device pivotal and RCT data for restorative neurostimulation (ReActiv8), PoNS/TLNS de novo and RCT evidence for gait/balance, and controlled trials of percutaneous modalities (e.g., PENFS pediatric RCTs). Independent HTAs and evidence organizations (Hayes, ECRI) and multiple systematic reviews and meta-analyses are used to characterize evidence strength across modalities, often concluding low-to-very-low quality evidence and recommending further large RCTs for conclusive determinations.

Study/Source	Design & Population	Key Findings	Quality/Limitations
{"text":"Harvey 2010 RCT","status":""},{"text":"Randomized trial, 20 individuals with established SCI and unilateral quadriceps weakness","status":""},{"text":"ES superimposed on progressive resistance training increased voluntary quadriceps torque (mean diff 14 Nm, p=0.034)","status":""},{"text":"Small sample, uncertain clinical importance, unclear whether ES critical component","status":""}
{"text":"Sadowsky 2013 cohort","status":""},{"text":"Single-center matched cohort, chronic SCI (n~25 FES vs 20 controls)","status":""},{"text":"FES cycling associated with higher CMSS responder rate (80% vs 40%), increased muscle mass/strength and improved QOL","status":""},{"text":"Nonrandomized, single-center, small sample","status":""}
{"text":"Máté 2023 systematic review","status":""},{"text":"Systematic review/meta-analysis of hybrid FES cycling in SCI (13 studies, n total small; 119 participants)","status":""},{"text":"Hybrid FES cycling improved VO2peak vs arm crank ergometry; emerging evidence for aerobic fitness benefits","status":""},{"text":"Included small, heterogeneous studies with methodological limitations and potential publication bias","status":""}
{"text":"Matsumoto 2023 (WalkAide)","status":""},{"text":"Multicenter RCT, n=203 subacute stroke patients with foot drop","status":""},{"text":"No significant improvement in barefoot 6MWT distance or walking speed vs control; concluded no efficacy in this population","status":""},{"text":"Large RCT but open-label; population limited to convalescent Japanese stroke patients","status":""}
{"text":"Hayes HTA (acute/subacute & chronic stroke)","status":""},{"text":"Health Technology Assessments reviewing multiple RCTs for FES for foot drop","status":""},{"text":"Overall low-quality evidence; skin-surface FES not superior to AFOs for walking/QOL; inconclusive for consistent functional recovery","status":""},{"text":"Heterogeneous studies, small sizes, short follow-up; recommends more RCTs","status":""}
{"text":"Zeng et al. 2024 (CHF) meta-analysis","status":""},{"text":"Systematic review/meta-analysis of RCTs in chronic heart failure (18 RCTs, n=777)","status":""},{"text":"FES improved peak VO2, 6MWD and QOL vs control though traditional exercise was more effective","status":""},{"text":"Included small RCTs, heterogeneity in interventions and short follow-up","status":""}
{"text":"Kadoglou 2017 RCT (CHF)","status":""},{"text":"Randomized placebo-controlled trial, n=120, 6-week FES vs placebo","status":""},{"text":"FES reduced HF-related hospitalizations vs placebo; no mortality difference","status":""},{"text":"Medium sample, limited to six-week program with longer follow-up observationally","status":""}
{"text":"ReActiv8 RCT (Gilligan 2021)","status":""},{"text":"Randomized double-blind sham-controlled multicenter trial, n=240, refractory mechanical CLBP with multifidus dysfunction","status":""},{"text":"Reported 64% with ≥50% LBP improvement; between-group difference at 120 days small; benefits in long-term follow-ups reported","status":""},{"text":"Marginal between-group difference at primary endpoint; attrition and risk of bias noted in assessments","status":""}
{"text":"ECRI / Hayes assessments (ReActiv8, PNS, Scrambler, others)","status":""},{"text":"Independent HTA/CEA reviews summarizing device evidence across indications","status":""},{"text":"Generally found insufficient, low or minimal support for many device-indication pairs; recommended further high-quality RCTs","status":""},{"text":"Depend on included study quality; many bodies note heterogeneity and limited durability data","status":""}
{"text":"Goree 2024 PNS (post-TKA) RCT","status":""},{"text":"Multicenter double-blind randomized placebo-controlled crossover trial, percutaneous PNS for persistent post-TKA pain (n~52)","status":""},{"text":"60% responded (≥50% pain relief) with 60-day PNS vs 24% with placebo; improved walking distance","status":""},{"text":"Small trial but randomized and placebo-controlled; limited generalizability, short lead duration","status":""}
{"text":"PoNS device (FDA de novo) and TLNS trials","status":""},{"text":"Device approvals and small RCTs/pilot studies in gait/balance (TBI, MS)" ,"status":""},{"text":"Small RCTs show possible gait/balance benefits when PoNS/TLNS combined with PT but evidence inconclusive and often device-developer centers","status":""},{"text":"Small samples, limited independent replication; FDA de novo indicates limited population-specific labeling","status":""}
{"text":"Hayes / ECRI HTAs summary entries","status":""},{"text":"Multiple HTAs and ECRIs across modalities (FES, PNS, ReActiv8, Scrambler, PENFS) aggregated evidence conclusions","status":""},{"text":"Consistent theme: many positive signals in small/single-center trials but overall low-to-very-low quality evidence; guidelines often advise further research or against routine use","status":""},{"text":"HTAs limited by available studies; recommend larger, standardized RCTs","status":""}

Medicare Determinations

Name	Effective Date	Type	Number/Link
{"text":"Functional Electrical Stimulation (FES) - Coverage and HCPCS Coding","status":""},{"text":"2019-09-05","status":""},{"text":"NCD","status":""},{"text":"","status":""}

Revision History

03/01/2025revised

Applicable Codes: Revised description for HCPCS code E0721; Supporting Information sections (Description of Services, Clinical Evidence, FDA, and References) updated; previous policy version CS036.W archived.

03/01/2025clarified

Medical Records Documentation Used for Reviews reference link updated (administrative/template update).

06/01/2025revised

Application: Added language indicating the Medical Policy does not apply to Idaho and Kansas; refer to state-specific policy versions (administrative/template update).